Abstract
Background: Cancer patients are vulnerable to infections, are older and often have comorbidities in comparison to the general population, which increases the risk for severe outcomes related to COVID-19 diagnosis. Methods: This study is a prospective, nationwide study in patients with solid cancer and SARS-CoV-2 infection included between 10 March to 15 June 2020. Patient's baseline characteristics were collected. The study’s primary outcome was overall survival within 30 days of verified SARS-CoV-2 infection. Secondary outcomes were hospital admission, admission to an ICU, and need for supplemental oxygen. Results: A total of 112 patients with a cancer diagnosis and verified SARS-CoV-2 infection were identified. After one month of follow up, hospitalization was required for 54% (n = 61) and 21% of the patients had died and 14 of the 23 deceased cancer patients were ≥70 years. Most patients were classified with mild COVID-19 symptoms (66%, n = 74); however, 48% (n = 23) of the ≥70-year-olds patients were classified with severe or critical COVID-19 symptoms. Among the total study population, 61% (n = 68) had comorbidities and comorbidity were more frequently observed among the deceased (91%, n = 21) and older cancer patients (≥70 years, 81%, n = 39). Conclusions: Acknowledging the low sample size in this study, our work shows that age and comorbidities, but not recent cytotoxic therapy, are associated with adverse outcomes of SARS-CoV-2 infection for patients with solid cancer. Particularly, patients with progressive disease seem to be at greater risk of a fatal outcome from COVID-19.Highlights Age, performance status, and comorbidities are strong predictors of adverse outcome in cancer patients with SARS-CoV-2 infection. Patients with progressive cancer disease seem to be at greater risk of a fatal outcome from COVID-19. Recent cytotoxic therapy, however, did not seem to be associated with increased risk for adverse outcomes of SARS-CoV-2 infection for patients with solid cancer.
Original language | English |
---|---|
Journal | Acta Oncologica |
Volume | 60 |
Issue number | 7 |
Pages (from-to) | 859-865 |
Number of pages | 7 |
ISSN | 0284-186X |
DOIs | |
Publication status | Published - 2021 |
Keywords
- cancer
- comorbidity
- COVID-19
- prognosis
- SARS-CoV-2
- survival
Fingerprint
Dive into the research topics of 'Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study'. Together they form a unique fingerprint.Datasets
-
Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study
Ehmsen, S. (Creator), Jakobsen, L. H. (Creator), Lendorf, M. E. (Creator), Eefsen, R. L. (Creator), Bentsen, L. (Creator), Knoop, A. S. (Creator), Aggerholm-Pedersen, N. (Creator), Skuladottir, H. (Creator), Herrstedt, J. (Creator), Jensen, L. H. (Creator), Rotbøl, C. (Creator), Damm, M. B. (Creator), Wedervang, K. (Creator), Glenthøj, A. (Creator), Ryg, J. (Creator), Frederiksen, H. (Creator) & Kodahl, A. R. (Creator), Taylor & Francis, 2021
DOI: 10.6084/m9.figshare.14135228.v1, https://tandf.figshare.com/articles/journal_contribution/Severity_and_1-month_outcome_of_SARS-CoV-2_infection_in_patients_with_solid_cancers_a_Danish_nationwide_cohort_study/14135228/1
Dataset: Supplementary material